It's one down, one to go for Amylin Pharmaceuticals Inc., which won a hard-fought approval by the FDA of injectable Symlin (pramlintide acetate) for patients with Type I or Type II diabetes, whose insulin is not giving them glucose control. (BioWorld Today) Read More